Brazil Threatens To Break Merck’s Efavirenz Patent

Law360, New York (April 26, 2007, 12:00 AM EDT) -- Brazil on Wednesday reportedly threatened to break Merck & Co. Inc.’s patent on HIV/AIDS drug Efavirenz, warning it will tap into India’s generic drug industry if the pharmaceutical giant will not offer the country a lower price for the much-needed medicine.

Health Minister Jose Gomes Temporao on Wednesday identified Efavirenz, an antiretroviral drug used to treat HIV and AIDS, as a "public interest" medicine and gave Merck one week to negotiate a discounted price with the Brazilian government, the Associated Press reported.

If negotiations fail, Brazil...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.